RF Ablation Proving Itself in Barrett’s Esophagus

From PRNewswire and Bio-Medicine.org… link.

Untreated epithelium in Barrett's esophagus

Results presented at this week’s Digestive Disease Week meeting in Chicago illustrated the effectiveness of BÂRRX Medical, Inc.’s HALO ablation system in the treatment of the pre-cancerous condition known as Barrett’s esophagus. The HALO ablation system uses radiofrequency (RF) energy to remove the epithelium in the esophagus of patients with Barrett’s esophagus (see image at right). In addition to these cell’s being pre-cancerous, Barrett’s esophagus is associated with chronic gastroesophageal reflux disease (GERD).

Results from a number of clinical trials were presented during the Digestive Disease Week (DDW) in Chicago this week, revealing new outcomes data related to endoscopic radiofrequency ablation using the HALO ablation system for eradicating a pre-cancerous esophageal condition known as Barrett’s esophagus. Among them, reports included durability outcomes from a randomized sham-controlled trial, safety and efficacy outcomes from a large U.S. registry of 429 patients, a randomized trial comparing ablation to endoscopic resection, and the largest European series to date in patients with high-grade dysplasia and early cancer.

As the DDW meeting commenced, the New England Journal of Medicine published a landmark paper entitled, "Radiofrequency Ablation for Barrett’s Esophagus Containing Dysplasia."  This is a U.S. randomized sham-controlled trial demonstrating high rates of complete eradication of barrett’s and dysplasia in the ablation group as compared to control, as well as a significant reduction in cancer progression.  At DDW, researchers presented new data from this now published trial showing that the ablation effect achieved at 1 year follow-up was highly durable at the 2-year follow-up.  

RF ablation is among a wide-range of energy-based technologies — cryo, microwave, laser, ultrasound, etc. — that are progressively penetrating virtually all clinical specialties where there is a need to selectively, with good clinical control and outcomes, therapeutically remove or ablate tissues.

(See the MedMarket Diligence report #a125, "Worldwide Ablation Technologies, 2008-2017", described at link.)

Posted via email from medmarket’s posterous

Leave a Reply